Abstract
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Current Drug Targets
Title:Molecular Pathophysiology of Priapism: Emerging Targets
Volume: 16 Issue: 5
Author(s): Uzoma A. Anele, Belinda F. Morrison and Arthur L. Burnett
Affiliation:
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Abstract: Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Export Options
About this article
Cite this article as:
Anele A. Uzoma, Morrison F. Belinda and Burnett L. Arthur, Molecular Pathophysiology of Priapism: Emerging Targets, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111842
DOI https://dx.doi.org/10.2174/1389450115666141111111842 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Serpinins: Role in Granule Biogenesis, Inhibition of Cell Death and Cardiac Function
Current Medicinal Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Short-term High-Dose Effect of Lovastatin on Thrombolysis by rt-PA in a Human Whole-Blood in vitro Clot Model
Current Neurovascular Research Sigma Receptor Activation Reduces Infarct Size at 24 Hours After Permanent Middle Cerebral Artery Occlusion in Rats
Current Neurovascular Research Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Subject Index to Volume 9
Current Pharmaceutical Design Cross-Talk Between Nitric Oxide and Transforming Growth Factor- β1 in Malaria
Current Molecular Medicine Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design